TAIPEI, Oct. 3, 2022 /PRNewswire/ -- AeroRx Therapeutics,
LLC. (AeroRx) and HCmed Innovations Co., Ltd. (HCmed) have
initiated a collaboration, introducing a LABA/LAMA combination
solution for delivery with a breath-actuated nebulizer. This
collaboration sets forth the framework by which both companies will
work together to develop a new nebulized combination formulation
for the treatment of chronic obstructive pulmonary disease
(COPD).
According to market reports, it is estimated that there would be
close to 34.5 million COPD patients worldwide by 2028, accounting
for treatment global sales that could reach up to 19.3 billion USD. AeroRx is currently developing
the first nebulized LABA/LAMA combination solution, which could
benefit 7-19% of the COPD population. This population group is
characterized for suffering from moderate to severe airflow
obstruction, which creates difficulties to achieve the inspiratory
flow rate required to use most dry powder inhalers optimally. Under
this partnership, AeroRx will be responsible for the formulation
development, clinical trials, and commercialization of the drug
product, while HCmed will be responsible for the customization of
the AdheResp breath-actuated nebulizer platform, analyzing and
optimizing the formulation's aerosol characterization performance
to accommodate the various stages of drug development process and
the final combination product. The project will follow a 505(b)2
regulatory pathway, and the corresponding PK/PD study is expected
to be conducted with HCmed's nebulizer in 2023.
Jason Cheng, CEO and founder of
HCmed, mentioned, "We are excited to announce our partnership with
AeroRx. The AeroRx team has extensive experience in the development
of respiratory drugs, while at HCmed we can support our partners to
develop drug-nebulizer combination products with our proprietary
breath-actuated mesh nebulizer platform. The product of our
collaboration will provide COPD patients with an effective inhaled
LABA/LAMA combination drug, which will reinforce patients'
treatment adherence and improve their quality of life."
Keith Ung, President and
co-founder of AeroRx also commented, "We too are enthusiastic about
this partnership. Breath-actuated vibrating mesh delivery of
inhaled therapeutics is the wave of the future for many
therapeutics and HCmed has become one of the leaders in this
elegant inhaler device technology."
About HCmed
Founded in 2014, HCmed Innovations Co.,
Ltd. (HCmed) is a contract development and manufacturing
organization that provides high-quality and cost-effective
vibrating mesh nebulizer technology and services to support global
pharmaceutical partners in the development of drug-nebulizer
combination products for inhalation therapy. HCmed offers a mature
customizable mesh nebulizer platform to enhance drug delivery. This
technology enables efficient and reliable nebulization of different
types of medication, ranging from small molecule synthetics to
large molecule biologics, as either solutions, suspensions, or even
difficult-to-deliver high viscosity drugs. For additional
information about HCmed, please visit www.hcmed-inno.com .
About AeroRx
Founded in 2022, AeroRx Therapeutics,
LLC. is a spin-off of iPharma Lab's inhalation CDRO business which
was recently acquired by Kindeva Drug Delivery (June 2022). AeroRx is developing proprietary
inhaled products for the treatment of COPD and asthma. The
company is led by industry veterans with extensive expertise in
inhaled drug delivery and development as well as a track record in
building new pharmaceuticals organizations from the ground
up.
View original
content:https://www.prnewswire.co.uk/news-releases/aerorx-partners-with-hcmed-to-develop-a-nebulized-labalama-combination-solution-for-the-treatment-of-chronic-obstructive-pulmonary-disease-301637960.html